Zimmer Biomet Acquires Monogram Technologies to Enhance Robotic Surgery Capabilities

Zimmer Biomet Holdings, Inc. has announced the acquisition of Monogram Technologies Inc., an innovative orthopedic robotics company. Under the terms of the deal, Zimmer Biomet will acquire all outstanding shares of Monogram for $4.04 per share, equating to an equity value of $177 million and an enterprise value of $168 million. Both companies' boards of directors have unanimously approved the transaction. Ivan Tornos, Zimmer Biomet's Chairman, President, and CEO, commented, “Monogram’s technology represents a major advancement, reinforcing our commitment to becoming the leader in surgical robotics and navigation. Once the acquisition is finalized, our customer-focused portfolio will boast the most comprehensive and flexible technology ecosystem, catering to a wide range of surgeons’ preferences—both now and in the future.” He added, “With Monogram's proprietary technology, Zimmer Biomet is poised to be the first company to introduce fully autonomous capabilities, redefining the standard of care and the future of orthopedic surgery.” Monogram Technologies, headquartered in Austin, Texas, has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology called mBôs, which received FDA 510(k) clearance in March 2025. The company anticipates commercializing mBôs with Zimmer Biomet implants in early 2027. Further, Monogram is working on a fully autonomous version of the mBôs system, which it believes could significantly enhance safety, efficiency, and surgical outcomes, with applications beyond total knee arthroplasty. Benjamin Sexson, CEO of Monogram, expressed enthusiasm about the acquisition, stating, “From the start, our aim has been to advance orthopedic robotics with technology that safely, efficiently, and accurately supports surgeons performing total knee arthroplasty. We are excited to bring our technology to Zimmer Biomet’s leading portfolio of surgical robotics, navigation solutions, and implants, leveraging their extensive industry experience and global reach.” Zimmer Biomet expects the acquisition to boost its revenue growth starting in 2027. Integrating mBôs into its existing lineup, particularly the ROSA platform, will enhance robotic knee adoption in the U.S. and expand Zimmer Biomet’s global knee offerings. The ROSA platform, which has recently expanded to include shoulder replacement, already supports four applications, including knee surgeries. With nearly 2,000 installations worldwide, the platform is widely recognized. Zimmer Biomet plans to continue advancing the ROSA system and has a robust R&D pipeline featuring several new products and software applications expected to launch by 2027. Notably, the company has submitted ROSA Knee with OptimiZe to the FDA for 510(k) clearance, with approval expected later this year. Additional updates include the upcoming commercial launch of ROSA Posterior Hip and the full commercialization of ROSA Shoulder. Zimmer Biomet has also collaborated with THINK Surgical Inc. to integrate the Persona system with the TMINI surgical robot. By incorporating Monogram’s cutting-edge technologies, Zimmer Biomet aims to address diverse surgical preferences, ranging from CT and non-CT imaging, robotic and non-robotic procedures, manual and surgeon-centered methods, to semi- and fully autonomous systems. This enhanced portfolio will support surgeons throughout the entire surgical process—from pre-operative planning to intraoperative guidance and post-operative care, ensuring better patient outcomes and operational efficiency.